ATG-102, a novel LILRB4 x CD3 T cell engager, targeting two nonoverlapping epitopes of LILRB4, for the treatment of monocytic AML

被引：0
|
作者：
Sun, Ao
Gao, Mengshi
Guo, Rong
Liu, Huiling
Hu, Zaoshun
Zheng, Enlin
Hui Yuwen
Chen, Peng
Mei, Jay
Shan, Bo
Hou, Bing
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-2372
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2372
引用
收藏
页数：2
相关论文
共 11 条
  • [1] LBL-043, a novel LILRB4xCD3 T cell engager, for the treatment of LILRB4 positive leukemia
    Dang, Yujia
    Huang, Xiao
    Qin, Yurong
    Liu, Xiaoya
    Chen, Min
    Jiang, Duqing
    Wu, Guojin
    Ye, Mi
    Sun, Jianming
    Wang, Baohui
    Guan, Jing
    Li, Tingting
    Zhu, Jordan
    Lai, Shoupeng
    Kang, Xiaoqiang
    Ling, Hong
    CANCER RESEARCH, 2024, 84 (06)
  • [2] A novel bispecific LILRB4/CD3 antibody with potent killing of monocytic acute myeloid leukemia cells
    Huang, Tao
    Hong, Kyu
    McCutcheon, Krista
    Ma, Jing-Tyan
    Zhu, Ying
    Deng, Mi
    Zhang, Cheng Cheng
    Woodard, Paul
    Xiang, Hong
    Schebye, Xiao Min
    Liao, X. Charlene
    CANCER RESEARCH, 2023, 83 (08)
  • [3] A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML
    John, Samuel
    Chen, Heyu
    Deng, Mi
    Gui, Xun
    Wu, Guojin
    Chen, Weina
    Li, Zunling
    Zhang, Ningyan
    An, Zhiqiang
    Zhang, Cheng Cheng
    MOLECULAR THERAPY, 2018, 26 (10) : 2487 - 2495
  • [4] Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development
    Gui, Xun
    Deng, Mi
    Song, Hao
    Chen, Yuanzhi
    Xie, Jingjing
    Li, Zunling
    He, Licai
    Huang, Fangfang
    Xu, Yixiang
    Anami, Yasuaki
    Yu, Hai
    Yu, Chenyi
    Li, Leike
    Yuan, Zihao
    Xu, Xiaoying
    Wang, Qihui
    Chai, Yan
    Huang, Tao
    Shi, Yi
    Tsuchikama, Kyoji
    Liao, X. Charlene
    Xia, Ningshao
    Gao, George F.
    Zhang, Ningyan
    Zhang, Cheng Cheng
    An, Zhiqiang
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (08) : 1244 - 1257
  • [5] Development of LILRB4 biparatopic synthetic T-cell receptor and antigen receptor (STAR)-T cells for the treatment of acute myeloid leukemia (AML)
    Rui, Wei
    Lei, Lei
    Zhang, Zezhong
    Wu, Chunyan
    Xia, Yu
    Liu, Yingying
    Pang, Xiaojing
    Du, Ruifang
    Wang, Lan
    Sheng, Dengyue
    Guo, Jing
    Zhang, Yanyan
    Zhao, Xueqiang
    Pan, James
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Microglia LILRB4 upregulation reduces brain damage after acute ischemic stroke by limiting CD8+ T cell recruitment
    Ma, Yilin
    Zheng, Kai
    Zhao, Chengcheng
    Chen, Jieli
    Chen, Lin
    Zhang, Yue
    Chen, Tao
    Yao, Xiuhua
    Cai, Ying
    Wu, Jialing
    JOURNAL OF NEUROINFLAMMATION, 2024, 21 (01)
  • [7] Lbl-043, a Novel LILRB4xCD3 T Cell Engager, for the Treatment of Relapsed/Refractory Multiple Myeloma
    Dang, Yujia
    Huang, Xiao
    Qin, Yurong
    Liu, Xiaoya
    Chen, Min
    Jiang, Duqing
    Ye, Mi
    Wu, Guojin
    Sun, Jianming
    Guan, Jing
    Zhu, Jordan
    Cai, Shengli
    Lai, Shoupeng
    Kang, Xiaogiang
    Ling, Hong
    BLOOD, 2024, 144 : 5827 - 5827
  • [8] Antibodies to ILT3 (LILRB4) abrogate myeloid immunosuppression and combine with PD1 blockade to enable T cell activation and function
    Brandish, Philip
    Baker, Jeanne
    Byford, Alan
    Caniga, Michael
    Chappell, Craig
    Cherwinski, Holly
    Cua, Daniel
    Fayadat-dilman, Laurence
    Hall, Brian
    Joyce-Shaikh, Barbara
    Juan, Veronica
    Mieczkowski, Carl
    Palmieri, Anthony
    Qu, Yujie
    Singh, Latika
    Stiivers, Peter
    Zhang-Hoover, Jie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [9] Novel conditionally active bispecific HER2 x CD3 T cell engager targeting solid tumors
    Cugnetti, Ana Paula
    Liu, Haizhen
    McNeeley, Patricia
    Wheeler, Christina
    Lucas, Matthew
    Xing, Charles
    Joyner, Solmarie
    Johnson, Kyrie
    Woodard, Kathryn
    Zhou, Wei
    Chang, Cathy
    Frey, Gerhard
    Boyle, William J.
    Short, Jay M.
    CANCER RESEARCH, 2023, 83 (07)
  • [10] A multispecific T cell engager binding to both membrane proximal and membrane distal epitopes of MSLN with low affinity CD3 for the treatment of AML and solid tumors.
    Yang, Cuiqing
    Shao, Xiaohui
    Zhou, Feng
    Zhou, Lei
    Deng, Qi
    Zhang, Yun
    Cheng, Guangcun
    Hu, Yingying
    Ma, Huaiyuan
    Wu, Yadan
    Wang, Shuai
    Zang, Jie
    Liu, Lei
    Yang, Wenqing
    Liu, Yang
    Xia, Chunlei
    Hu, Jianzhong
    Luo, Ande
    Fu, Yayuan
    Cao, Zhuoxiao
    Tang, Renhong
    CANCER RESEARCH, 2022, 82 (12)
12